作者
Robert C Doebele, Xian Lu, Christopher Sumey, DeLee A Maxson, Andrew J Weickhardt, Ana B Oton, Paul A Bunn Jr, Anna E Barón, Wilbur A Franklin, Dara L Aisner, Marileila Varella‐Garcia, D Ross Camidge
发表日期
2012/9/15
期刊
Cancer
卷号
118
期号
18
页码范围
4502-4511
出版商
Wiley Subscription Services, Inc., A Wiley Company
简介
BACKGROUND
The discovery of distinct subsets of nonsmall cell lung cancer (NSCLC) characterized by activation of driver oncogenes has greatly affected personalized therapy. It is hypothesized that the dominant oncogene in NSCLC would be associated with distinct patterns of metastatic spread in NSCLC at the time of diagnosis.
METHODS
A total of 209 consecutive patients with stage IV nonsquamous NSCLC with an EGFR (epidermal growth factor receptor) mutation (N = 39), KRAS (v‐Ki‐ras2 Kirsten rat sarcoma viral oncogene homolog) mutation (N = 49), ALK (anaplastic lymphoma receptor tyrosine kinase) gene rearrangement (N = 41), or wild‐type for all 3 (triple negative, N = 80) were included. The percentage of patients with metastatic disease at a given site was compared between each molecular cohort (EGFR, KRAS, or ALK) and the triple negative cohort.
RESULTS
ALK gene rearrangement was …
学术搜索中的文章
RC Doebele, X Lu, C Sumey, DLA Maxson… - Cancer, 2012